The overexpression of P-gp in tumors such as myelogenous leukemia, liver cancer and lung cancer correlates with poor chemotherapeutic treatment outcomes [6], [7], as P-gp expels hydrophobic drugs (e.g., paclitaxel, doxorubicin) out to the extracellular space [8]. The gene discussed is PGP; the disease is lung cancer.